AdaptHealth Names Suzanne Foster CEO
By Ben Glickman
AdaptHealth named Danaher executive Suzanne Foster as its next chief executive, ending a nearly 10-month search for the company's next leader.
Plymouth Meeting, Pa.-based AdaptHealth, which makes at-home medical equipment and supplies, said Foster was previously president of Beckman Coulter Life Sciences, owned by Danaher. She has also held roles at Cardinal Health At-Home Solutions and Stanley Healthcare.
She will take over as CEO effective May 20.
Foster succeeds interim CEO Richard Barasch, who stepped in to lead the company after the departure of CEO Stephen Griggs in June.
AdaptHealth previously named Crispin Teufel as Griggs' successor in June. That appointment was challenged by Linde, Teufel's former employer. Linde sued Teufel to stop his move to AdaptHealth.
Barasch has continued to serve as interim CEO until a permanent successor could be appointed. AdaptHealth said Barasch would continue to serve as chairman until June 30, after which he will step down from the board.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 17, 2024 16:57 ET (20:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?